Navigation Links
Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
Date:1/7/2008

sed on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our divestiture of non-strategic assets, our restructuring initiatives, our operational strategy, our financial performance and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
2. Boston Scientific Announces Results for Third Quarter Ended September 30, 2007
3. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
4. The 58th Annual Meeting of the American Association for the Study of Liver Diseases, Boston, Nov. 2-6
5. Boston Scientific Announces European Approval of Next-Generation Implantable Defibrillator
6. Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetixs Medical Advisory Board
7. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
8. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
11. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... of three Department of Energy (DOE) bio-energy research centers, ... its valuable intellectual property. , ... ... -- Surety, LLC , the leading provider of ... the Joint BioEnergy Institute (JBEI), one of three Department ...
(Date:12/15/2009)... 15 Aethlon Medical, Inc. (OTC Bulletin ... Schorey and Dr. Wayne Comper have ... Inc. (ESI). Both Dr. Schorey and Dr. Comper ... a wholly owned subsidiary of Aethlon Medical, was ... Hemopurifier®, a medical device being advanced as an ...
(Date:12/15/2009)... -- The International Society for Medical Publication Professionals ... continuing to accept abstracts for its 6th Annual ... April 19-21, 2010. This marks the first time ... the organization to submit an abstract to this ... AM EST, January 15, 2010. For submission details, ...
(Date:12/15/2009)... December 15 , ... to Evaluate the Ability of,Cardiopoietic Cells to Restore ... BioSciences, a leading Belgian biotechnology company specialising,in cell-based ... that it has completed, two months ahead of ... Phase II/III trial of C-Cure, a,unique stem cell ...
Breaking Biology Technology:Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 2Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 3Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 4Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property 5Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 2The International Society for Medical Publication Professionals Announces Call for Abstracts for Its 6th Annual Meeting 3Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 2Cardio3 BioSciences Completes Patient Enrolment in First Stage of Pivotal Trial of C-Cure(R) in Heart Failure 3
... Ceres, Inc. announced today,that it has begun booking ... label. The highly anticipated launch marks the first seed,sales ... biofuels and biopower. The company simultaneously launched a Blade ... The company reported that the first Blade ...
... Cornerstone Therapeutics Inc. (Nasdaq: CRTX ), ... commercializing prescription medications for respiratory disorders, today provided ... activities following the closing of the business combination ... Inc. on October 31, 2008, and the renaming ...
... TORONTO, Dec. 11 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: ... tests for the early detection of diseases and ... entered into a agreement allowing Centocor Research & ... osteoarthritis genomic biomarker program. Additional terms of the ...
Other Biology Technology:First Seed Sales of Dedicated Energy Crops Begin 2First Seed Sales of Dedicated Energy Crops Begin 3Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 2Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 3Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 4Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance 5GeneNews provides Centocor access to its osteoarthritis program 2
(Date:12/15/2009)... a team of Spanish and American researchers found the fossil ... Huelva. Now they have published, for the first time, the ... the death of the young cetacean, possibly a baleen whale ... discovery of the partial fossil remains of a whale from ... Sands sedimentary formation, but it is the first time that ...
(Date:12/15/2009)... model organism, but there are currently few resources ... blood-forming tissues in this species. A newly ... from Cold Spring Harbor Laboratory Press fills this ... protocols for the preparation, enumeration, and microscopic examination ... tissues in the mouse. The laboratory manual ...
(Date:12/14/2009)... AlaskaScientists have identified a novel antifreeze molecule in a ... 100 degrees Fahrenheit. Unlike all previously described biological antifreezes ... little or no protein. It is composed of a ... new places within the cells of organisms. , ... this molecule is a whole new kind of antifreeze ...
Breaking Biology News(10 mins):Story of 4.5 million-year-old whale unveiled in Huelva 2Story of 4.5 million-year-old whale unveiled in Huelva 3New source of classical techniques for blood-based studies in the laboratory mouse 2Scientists isolate new antifreeze molecule in Alaska beetle 2Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 1Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 2Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 3Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 4Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 5Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 6Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 7Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 8Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 9Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 10Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 11Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 12Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 13Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 14Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 15Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 16Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 17Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 18Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 19Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 20Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 21Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics Market Forecasts to 2015 Competitive Benchmarking Product Pipeline an 62398 22Health Care Pioneer Henry J Kaiser Inducted Into The California Hall of Fame 62393 1Health Care Pioneer Henry J Kaiser Inducted Into The California Hall of Fame 62393 2Health Care Pioneer Henry J Kaiser Inducted Into The California Hall of Fame 62393 3FUJIFILM Europe Teams Synapse with Matrox Xenia 6663 1FUJIFILM Europe Teams Synapse with Matrox Xenia 6663 2FUJIFILM Europe Teams Synapse with Matrox Xenia 6663 3
... a few nights without enough sleep and you're more likely ... how sleep is related to the immune system. Now, researchers ... fruit flies can point to the answers. , What they ... may be a two-way street: sick flies can't sleep, and ...
... Researchers observing wild chimpanzees in Uganda have discovered repeated ... infanticide. The findings, reported by Simon Townsend, Katie Slocombe ... and the Budongo Forest Project, Uganda, appear in the ... by Cell Press. , Infanticide is known to occur ...
... early or localized prostate cancer, taking too many multivitamins ... or fatal prostate cancers, according to a study in ... the National Cancer Institute . , Millions of Americans ... health benefits, even though there is limited scientific evidence ...
Other Biology News:Sleepless for science: Flies show link between sleep, immune system in Stanford study 2Sleepless for science: Flies show link between sleep, immune system in Stanford study 3Female-led infanticide in wild chimpanzees 2Heavy multivitamin use may be linked to advanced prostate cancer 2